A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2
Authors
Keywords
Candesartan, Chemotherapy, Gemcitabine, Renin-angiotensin system, Pancreatic cancer
Journal
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 5, Pages 1294-1299
Publisher
Springer Nature
Online
2013-05-20
DOI
10.1007/s10637-013-9972-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
- (2012) Y Nakai et al. BRITISH JOURNAL OF CANCER
- Statins and cancer: Current and future prospects
- (2012) Maja Osmak CANCER LETTERS
- Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1
- (2012) Yousuke Nakai et al. CANCER SCIENCE
- The role of stroma in pancreatic cancer: diagnostic and therapeutic implications
- (2012) Mert Erkan et al. Nature Reviews Gastroenterology & Hepatology
- How Does Inhibition of the Renin-Angiotensin System Affect the Prognosis of Advanced Gastric Cancer Patients Receiving Platinum-Based Chemotherapy?
- (2012) Seung Tae Kim et al. ONCOLOGY
- Clinical Outcomes of Chemotherapy for Diabetic and Nondiabetic Patients With Pancreatic Cancer
- (2012) Yousuke Nakai et al. PANCREAS
- Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation
- (2012) Shanna A. Arnold et al. PLoS One
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review
- (2011) Úna C. Mc Menamin et al. CANCER CAUSES & CONTROL
- Angiotensin Receptor Blockade and Risk of Cancer in Type 2 Diabetes Mellitus: A Nationwide Case-Control Study
- (2011) Chia-Hsuin Chang et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine
- (2010) Y Nakai et al. BRITISH JOURNAL OF CANCER
- Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
- (2010) Ilke Sipahi et al. LANCET ONCOLOGY
- Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials
- (2010) Sripal Bangalore et al. LANCET ONCOLOGY
- Blocking Angiotensin II Type 1 Receptor Triggers Apoptotic Cell Death in Human Pancreatic Cancer Cells
- (2010) Qiaoke Gong et al. PANCREAS
- Does the Renin-Angiotensin System Participate in Regulation of Human Vasculogenesis and Angiogenesis?
- (2008) A. Y. Khakoo et al. CANCER RESEARCH
- The renin-angiotensin system and malignancy
- (2008) E. I. Ager et al. CARCINOGENESIS
- Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
- (2008) Nish Chaturvedi et al. LANCET
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
- (2008) Anne Katrin Sjølie et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now